AUTHORS
Nirav N. Shah, MD, MS, Katherine B Winfree, PhD2, Naleen Raj Bhandari, Ph.D3, Mohsen Soltanifar, PhD4, Tomoko Sugihara5, Arrin Kontos, PharmD6, Javier L. Munoz, MD, MBA7, Yucai Wang, MD, PhD8
AFFILIATIONS
1 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
2 Eli Lilly and Company, Indianapolis, Indiana, United States
3 Eli Lilly and Company, Indianapolis, Indiana, United States
4 IQVIA Inc, Mississauga, Ontario, Canada
5 Syneos Health, Morrisville, North Carolina, United States
6 Eli Lilly and Company, Indianapolis, Indiana, United States
7 Naples Comprehensive Health, Naples, Florida, United States
8 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Background:
Pirtobrutinib is a highly selective, non-covalent Bruton tyrosine kinase inhibitor (BTKi). It is approved in the United States (US) for adults with relapsed or refractory (R/R) mantle cell lymphoma (MCL) following ≥2 prior lines of systemic therapy, including a BTKi. Real-world (RW) evidence for pirtobrutinib in R/R MCL is emerging, with reports in Europe and the US describing use in heavily pretreated, covalent BTKi-exposed (cBTKi) patients. This study described RW patient characteristics and outcomes of pirtobrutinib in BTKi-pretreated patients with R/R MCL.
Methods:
This retrospective study used the US-based, electronic health record-derived Flatiron Health Research Database. Patients with MCL who received prior cBTKi treatment and initiated pirtobrutinib-containing therapy between 01/01/2023 and 01/31/2026 were included. Patient demographic and clinical characteristics were summarized with descriptive statistics for the overall cohort and a subgroup who received pirtobrutinib monotherapy immediately after discontinuation of cBTKi (cBTKi L-1 subgroup). Time-to-event RW outcomes were measured from the initiation of pirtobrutinib (index date). These include time-to-treatment discontinuation or death (TTDd), time-to-next treatment or death (TTNTd), and overall survival (OS), all estimated using the Kaplan-Meier method. All analyses were conducted using SAS software, v9.4.
Results:
A total of 310 patients were treated with pirtobrutinib after prior cBTKi, with the majority (67.7%) receiving pirtobrutinib monotherapy. Of patients treated with pirtobrutinib in combination (n=100), the most common regimen was pirtobrutinib + rituximab, with or without other therapies (48.0%). Median age was 75 years (IQR 67-80), and most patients were male (70.3%). Patients were predominantly treated in a community practice setting (63.2%). Among patients with documented Eastern Cooperative Oncology Group (ECOG) performance status, a score of ≥2 was reported in 15.5% (n=38/245). At the initiation of pirtobrutinib, Ki-67 ≥30% was observed in 67.4% (n=159/236) of patients, and blastoid or pleomorphic histology was reported in 12.3% (n=38/310). Median time from MCL diagnosis to pirtobrutinib initiation was 59.6 months (IQR 24.8-110.1). The median line of therapy in which pirtobrutinib was received in the overall cohort was 4 (IQR 3-5), with 15.8% receiving pirtobrutinib in the 6th line or later; 9.7% of patients had prior chimeric antigen receptor (CAR) T-cell therapy. Median follow-up time from initiation of pirtobrutinib was 8.4 months (IQR 3.0-15.4), and 23.2% of patients remained on pirtobrutinib at the time of this analysis. After pirtobrutinib, 20.6% of patients received CAR T-cell therapy. The median TTDd and TTNTd were 4.9 (95% CI 4.2-5.9) and 5.7 (95% CI 4.9-7.4) months, respectively. Median OS was 16.6 months (95% CI 13.0-21.6).
The cBTKi L-1 subgroup (n=161) received pirtobrutinib monotherapy immediately post-cBTKi. Baseline characteristics were largely consistent with the overall cohort. The ECOG performance status score ≥2 was reported in 8.8% (n=11/125) of patients, and 9.3% (n=15/161) had blastoid or pleomorphic histology. Despite representing patients who initiated pirtobrutinib immediately following cBTKi discontinuation, this subgroup remained heavily pretreated, with a median line of therapy of 3 (IQR 3-4) at pirtobrutinib initiation; 8.1% received pirtobrutinib in the 6th line or later, and 2.5% of patients had prior CAR T-cell therapy. Patients in the cBTKi L-1 subgroup had a median TTDd of 4.9 months (95% CI 4.2-5.9), TTNTd of 5.6 months (95% CI 4.9-8.0), and OS of 18.6 months (95% CI 12.7-NR).
Conclusion:
In this US RW study of heavily pretreated, older patients with R/R MCL, pirtobrutinib demonstrated meaningful TTDd, TTNTd, and OS outcomes, supporting the efficacy profile observed in clinical trials. Patients who received pirtobrutinib immediately following cBTKi had similar outcomes to the overall population. These outcomes were observed in more heavily pretreated patients with MCL than enrolled on the BRUIN registrational cohort. To our knowledge, this represents the first large-scale, US community-based analysis of pirtobrutinib in R/R MCL, capturing outcomes in patients typically underrepresented in clinical trials. These findings add to the emerging RW evidence for pirtobrutinib in BTKi-pretreated MCL and support its clinical effectiveness in a RW, community-based setting of significant unmet need.
DISCLOSURES
Nirav N. Shah, MD, MS: Nurix, Gilead-Kite, BMS-Juno, Miltenyi Biomedicine, Lilly Oncology, Incyte, AbbVie, BeoNE, Kite, AstraZeneca, Genentech, Tundra, Adaptive Biotechnologies - Current holder of stock options in a privately-held company; Tundra Therapeutics - Current holder of stock options in a privately-held company; Nurix, Gilead-Kite, BMS-Juno, Miltenyi Biomedicine, Lilly Oncology, Incyte, AbbVie, BeoNE, Kite, AstraZeneca, Genentech, Tundra, Adaptive Biotechnologies - Honoraria; Nurix, Gilead-Kite, BMS-Juno, Miltenyi Biomedicine, Lilly Oncology, Incyte, AbbVie, BeoNE, Kite, AstraZeneca, Genentech, Tundra, Adaptive Biotechnologies - Research Funding; Miltenyi Biomedicine - Research Funding; Lilly Oncology - Research Funding; Incyte - Consultancy (Includes expert testimony); BMS-Juno - Consultancy (Includes expert testimony); Legend - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Lilly Oncology - Consultancy (Includes expert testimony); BeOne - Consultancy (Includes expert testimony); Nurix, Gilead-Kite, BMS-Juno, Miltenyi Biomedicine, Lilly Oncology, Incyte, AbbVie, BeoNE, Kite, AstraZeneca, Genentech, Tundra, Adaptive Biotechnologies - Consultancy (Includes expert testimony); Miltenyi Biomedicine - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony)